Open access · CC-BY
via OpenAlex
Advances in Age-related Macular Degeneration Understanding and Therapy
Joan W. Miller, Saghar Bagheri, Demetrios G. Vavvas
touchREVIEWS in Ophthalmology · 2017 · ▲ 71 citations
Abstract
While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive to date, with a lack of effective therapies and increasing prevalence of the disease. There is an overwhelming need to improve the classification system of AMD, to increase our understanding of cell death mechanisms involved in both neovascular and non-neovascular AMD, and to develop better biomarkers and clinical endpoints to eventually be able to identify better therapeutic targets-especially early in the disease process. There is no doubt that it is a matter of time before progress will be made and better therapies will be developed for non-neovascular AMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.17925/usor.2017.10.02.119
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Miller, J.W., Bagheri, S., & Vavvas, D.G. (2017). Advances in Age-related Macular Degeneration Understanding and Therapy. <em>touchREVIEWS in Ophthalmology</em>. https://doi.org/10.17925/usor.2017.10.02.119
Vancouver
Miller JW, Bagheri S, Vavvas DG. Advances in Age-related Macular Degeneration Understanding and Therapy. touchREVIEWS in Ophthalmology. 2017. doi:10.17925/usor.2017.10.02.119.
BibTeX
@article{joan2017Advanc,
title = {Advances in Age-related Macular Degeneration Understanding and Therapy},
author = {Joan W. Miller and Saghar Bagheri and Demetrios G. Vavvas},
journal = {touchREVIEWS in Ophthalmology},
year = {2017},
doi = {10.17925/usor.2017.10.02.119},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Drugs 2008
Citation only
Neovascular Age-Related Macular Degeneration
Clinical ophthalmology 2009
Open access · CC-BY
Age-related macular degeneration: current treatments
Survey of Ophthalmology 2006
Citation only
The Genetics of Age-Related Macular Degeneration: A Review of Progress to Date
Survey of Ophthalmology 2000
Citation only
Mechanisms of Action of Photodynamic Therapy with Verteporfin for the Treatment of Age-Related Macular Degeneration
St. Erik Eye Hospital 2006
Open access · US-GOV
A Prospective, Randomized, Double-masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-related Macular Degeneration (AMD)
Ophthalmology 2004
Citation only